Janus Henderson Group PLC Acquires 8,100 Shares of Dianthus Therapeutics, Inc. $DNTH

Janus Henderson Group PLC lifted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 96.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,500 shares of the company’s stock after buying an additional 8,100 shares during the quarter. Janus Henderson Group PLC’s holdings in Dianthus Therapeutics were worth $1,384,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of DNTH. Vanguard Group Inc. increased its stake in Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares during the period. UBS Group AG boosted its stake in shares of Dianthus Therapeutics by 342.6% during the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after purchasing an additional 469,547 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Dianthus Therapeutics by 1,275.3% in the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock worth $19,606,000 after purchasing an additional 441,156 shares during the last quarter. SummitTX Capital L.P. grew its holdings in shares of Dianthus Therapeutics by 13.8% in the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after purchasing an additional 12,118 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in Dianthus Therapeutics by 155.5% in the 1st quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock worth $3,406,000 after buying an additional 24,697 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics News Summary

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target for Dianthus Therapeutics to $158 from $130 and maintained a “Buy” rating. The target implies additional upside and reflects the firm’s long-term expectations for the company’s complement-therapy pipeline. Dianthus Therapeutics Price Target Raised to $158
• Positive Sentiment: HC Wainwright improved several near- and long-term earnings forecasts, including narrowing its estimated 2026 loss to $3.87 per share from $4.81 and projecting a return to profitability by 2030 at $10.75 per share. The firm continues to rate DNTH “Buy” with a $158 target. HC Wainwright Dianthus Therapeutics estimates
• Positive Sentiment: Institutional interest has expanded, led by BlackRock’s approximately $402 million new position. Institutional investors now own about 47.5% of the stock, which may reinforce investor confidence and liquidity. Dianthus Therapeutics institutional ownership and insider trading
• Neutral Sentiment: Analyst views are generally favorable but not unanimous. DNTH has a “Moderate Buy” consensus, with 12 Buy ratings and one Sell rating; the average price target is $124.27, below HC Wainwright’s $158 objective. Analysts conflicted on Dianthus Therapeutics
• Negative Sentiment: CEO Marino Garcia sold 166,000 shares for approximately $17.9 million, reducing his direct holdings by 71.8%. Although the sale may be part of personal financial planning, its size can weigh on sentiment, particularly after the stock’s strong advance. Dianthus Therapeutics CEO stock sale
• Negative Sentiment: The company remains loss-making and recently missed quarterly EPS expectations, reporting a $0.90 loss per share versus an expected $0.85 loss. Revenue exceeded estimates, but the result highlights continued execution and funding risks for this clinical-stage biotech.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Truist Financial boosted their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Insider Buying and Selling

In related news, EVP Ryan Savitz sold 31,249 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Adam M. Veness sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the transaction, the senior vice president owned 30,000 shares in the company, valued at $2,424,000. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 253,779 shares of company stock valued at $25,931,495 in the last quarter. Corporate insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Price Performance

DNTH opened at $108.92 on Monday. The company has a market cap of $5.95 billion, a price-to-earnings ratio of -26.25 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 52-week low of $18.08 and a 52-week high of $114.55. The firm’s fifty day simple moving average is $94.72 and its two-hundred day simple moving average is $80.90.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. On average, research analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.